XML 39 R29.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($) $ in Thousands | Sep. 30, 2018 | Dec. 31, 2017
--- | --- | ---
Assets: |  |
Assets, fair value | $ 1,020,595 | $ 188,764
Liabilities: |  |
Liabilities, fair value | 12,731 | 13,961
Transferred over Time | Phase 3 Clinical Trial |  |
Liabilities: |  |
Contract asset | 10,000 |
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties |  |
Liabilities: |  |
Contract asset | 375,000 |
Maximum | Transferred over Time | Milestone Payments and Royalties |  |
Liabilities: |  |
Contract asset | 529,000 |
Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 7,401 | 8,401
Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 514 | 1,589
Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 4,816 | 3,971
Short-term investments |  |
Assets: |  |
Assets, fair value | 996,311 | 181,041
Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Investment in Warrants |  |
Assets: |  |
Assets, fair value | 24,284 | 3,846
Quoted Prices in Active Markets for Identical Assets (Level 1) |  |
Assets: |  |
Assets, fair value | 131,150 | 5,742
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments |  |
Assets: |  |
Assets, fair value | 106,866 | 1,896
Quoted Prices in Active Markets for Identical Assets (Level 1) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | 24,284 | 3,846
Significant Other Observable Inputs (Level 2) |  |
Assets: |  |
Assets, fair value | 889,445 | 179,145
Liabilities: |  |
Liabilities, fair value | 4,816 | 3,971
Significant Other Observable Inputs (Level 2) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 4,816 | 3,971
Significant Other Observable Inputs (Level 2) | Short-term investments |  |
Assets: |  |
Assets, fair value | 889,445 | 179,145
Significant Other Observable Inputs (Level 2) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Liabilities: |  |
Liabilities, fair value | 7,915 | 9,990
Significant Unobservable Inputs (Level 3) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 7,401 | 8,401
Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 514 | 1,589
Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) | Short-term investments |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Significant Unobservable Inputs (Level 3) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | $ 0 | $ 0

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_MilestonePaymentsAndRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_CurrentPortionofLiabilityForContingentValueRightsCompanyCrystalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_CurrentPortionofLiabilityForContingentValueRightsCompanyCydexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |